Fluocinolone Acetonide utained Drug Delivery Device for Chronic Central Retinal Vein Occluion: 12-Month Reult Original Reearch Article

Purpoe To determine treatment outcome of a long-acting intravitreal fluocinolone acetonide utained drug delivery implant in eye with central retinal vein occluion (CRVO) and chronic refractory macular edema. Deign Propective, noncomparative, interventional cae erie. Method Fourteen eye of 14 patient with chronically peritent macular edema aociated with CRVO underwent intraocular implantation of a three-year fluocinolone acetonide utained drug delivery ytem. Bet-corrected Early Treatment of Diabetic Retinopathy viual acuity (VA), central foveal thickne determined by optical coherence tomography, and intraocular preure (IOP) were recorded after the firt 12 month after implant inertion. Reult The median (range) vein occluion and macular edema duration were 12.5 month (range, even to 49). No eye experienced intraoperative complication. At baeline, median VA wa 20/126, improved to 20/60 by two month, and wa 20/80 by 12 month. A ignificant proportion of eye had gained line of VA at 12 month compared with baeline (P = .002). At 12 month, the mean and median central retinal thickne decreaed from 622 and 600 μm before urgery, repectively, to 307 and 199 μm after urgery, repectively (P = .008). By month 12, cataract had developed in all five phakic patient, and 13 of 14 eye required medical or urgical IOP-lowering intervention. Concluion VA improved and macular edema decreaed in a ignificant proportion of implanted eye with chronic, CRVO-aociated macular edema. Cataract formation and elevated IOP, the main ide effect, were managed, repectively, with cataract extraction and medical or urgical IOP control, or both. Thi ytem i a promiing novel alternative to currently available treatment for thi challenging patient population.